Table 4. Hazard ratios for CRC-specific mortality according to mode of detection and stage at diagnosis and location of tumor.

Patient / tumor characteristics, mode of detection	Deaths	Person-years	Rate per 1,000 person-yrs	Fully adjusted hazard ratio a
				HR	95% CI
Stage I + II
Symptoms	60	3225	18.6	1.00	Ref.
Any screening	8	1410	5.7	0.29	(0.14-0.61)
Other	5	528	9.5	0.46	(0.18-1.17)
Stage III
Symptoms	102	1983	51.4	1.00	Ref.
Any screening	10	547	18.3	0.33	(0.17-0.64)
Other	14	266	52.6	0.86	(0.47-1.57)
Stage IV
Symptoms	209	597	350.1	1.00	Ref.
Any screening	14	72	194.4	0.52	(0.30-0.90)
Other	37	105	352.4	0.92	(0.64-1.31)
Stage II-III patients who received chemotherapyb
Symptoms	98	2452	40.0	1.00	Ref.
Any screening	7	583	12.0	0.26	(0.12-0.56)
Other	11	270	40.7	0.69	(0.35-1.36)
Stage II-III patients who did not receive chemotherapy
Symptoms	84	2443	34.4	1.00	Ref.
Any screening	10	621	16.1	0.45	(0.23-0.87)
Other	7	312	22.4	0.67	(0.30-1.48)
Proximal colon
Symptoms	112	1380	81.2	1.00	Ref.
Any screening	11	721	15.3	0.32	(0.17-0.60)
Other	22	431	51.0	0.65	(0.40-1.04)
Distal colon
Symptoms	91	1627	55.9	1.00	Ref.
Any screening	10	670	14.9	0.47	(0.24-0.93)
Other	20	225	88.9	1.40	(0.85-2.31)
Rectum
Symptoms	168	2799	60.0	1.00	Ref.
Any screening	11	653	16.8	0.47	(0.25-0.86)
Other	14	230	60.9	0.70	(0.40-1.22)

FOBT, fecal occult blood test; HR, hazard ratio; 95% CI, 95% confidence interval

^aAdjusted for age, sex, education, stage and location of the cancer, and for time-dependent effects of age, sex, stage and location.

^bColon cancer patients who received chemotherapy after surgery for treatment of primary cancer; rectum cancer patients who received neoadjuvant therapy before surgery and/or chemotherapy after surgery for treatment of primary cancer.